CVS Health (CVS) The 2016 Morgan Stanley Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
The 2016 Morgan Stanley Global Healthcare Conference summary
4 Nov, 2026PBM value and drug cost management
2016 YTD drug trend ran at 3.5% YoY, versus drug price inflation above 9%; formulary strategies were projected to save clients more than $9B from 2012 through 2017.
Most negotiated manufacturer rebates went to clients; contracts specified compensation, and clients had transparency and audit rights.
PBM tools included lower-cost generic plan designs, formulary negotiation, prior authorization and utilization management; 2016–17 selling interest centered on specialty cost controls and formulary management.
Management advocated faster FDA generic approvals and biosimilar launches to increase competition and help lower drug costs.
Competitive position and business wins
The 2016–17 selling season had $7.4B in gross wins, $4.6B in net business and 97.5% retention, as reported on the August earnings call.
Gross new business wins exceeded $30B over the prior three years; management cited a growing market as more people gained coverage and plans outsourced pharmacy benefits.
Consumer-facing assets included 9,600 pharmacies, MinuteClinics, specialty and infusion services, and long-term care capabilities; the Health Engagement Engine linked services to support adherence and care coordination.
Maintenance Choice, Pharmacy Advisor and Specialty Connect were cited as differentiated offerings supporting adherence, affordability and continuity of care.
Health plan growth and integration
More than 70 health plans used pharmacy benefit services; excluding Medicare, health plans represented about 60% of revenue, versus a roughly 50/50 mix a few years earlier.
Management cited Medicaid expansion in about 30 states, further potential in Texas and Florida, and Medicare growth from 10,000 people reaching age 65 each day for another 14–15 years.
NovoLogix integrated pharmacy and medical data to manage pharmacy spending billed through medical benefits and reduce costs; health plan clients worked with the service to apply the technology.
Of serviced Medicare Part D health plans, 73% had four-star-or-higher performance, up from 53% the prior year.
Latest events from CVS Health
- Separation aims to unlock standalone growth while preserving investment-grade balance sheets.CVS
8th Annual Wolfe Research Healthcare Conference - Care delivery expansion and post-deleveraging capital choices shape the forward strategy.CVS
30th Annual Credit Suisse Healthcare Conference - Integrated pharmacy scale supported growth and more than $5B in planned 2016 shareholder returns.CVS
The UBS 2016 Global Healthcare Conference - Integrated pharmacy and clinical programs aim to improve outcomes and reduce care costs.CVS
UBS Global Healthcare Conference 2017 - Signify bolsters in-home care and value-based strategy amid stable utilization.CVS
Morgan Stanley 20th Annual Global Healthcare Conference - Aetna integration targets >$750M in 2020 synergies and broader medical-cost savings.CVS
JP Morgan 37th Annual Healthcare conference - Cost savings and payer partnerships support long-term growth and shareholder returns.CVS
Investor Day 2016 - A $77B Aetna deal targets integrated care and $750M in year-two synergies.CVS
M&A announcement - FY18 operating profit growth guided to 1%–4%, tempered by PBM and deal-related headwinds.CVS
Guidance